hydroxychloroquine

P1/2, N=93, Recruiting, VA Office of Research and Development | Not yet recruiting --> Recruiting

P2, N=25, Terminated, University Hospital, Rouen | Completed --> Terminated; Difficulty in enrolling new patients

P2, N=20, Terminated, Cancer Trials Ireland | Trial completion date: Jun 2026 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2025 --> Mar 2026; Study terminated due to futility

Treatment with immunosuppressants such as corticosteroids, hydroxychloroquine, and azathioprine resulted in symptomatic improvement. However, the disease course was complicated by constrictive pericarditis requiring pericardiectomy and later inflammatory arthritis requiring escalation of immunosuppression. This case highlights the importance of considering autoimmune etiologies in patients with unexplained multisystem effusions and elevated tumor markers, thereby avoiding misdiagnosis and unnecessary oncological interventions.

Patients receiving long-term HCQ/SSZ therapy generally showed improved clinical outcomes. This study suggests that HCQ/SSZ may reverse chemoresistance by reprogramming the inflammatory-immune microenvironment, offering a molecular rationale for further investigation into their repurposing as chemosensitizers and maintenance therapies in OC.

Late autophagy inhibition using hydroxychloroquine broadly sensitized both morphotypes, reducing enlarged cells. Notably, the senolytics dasatinib preferentially eliminated E-state cells. These findings highlight the plasticity and heterogeneity of TMZ-induced senescent glioblastoma cells and emphasize the need for selective senotherapeutic strategies aiming to attenuate the pro-tumor effects exerted by SnCs on the tumor microenvironment.

P2, N=0, Withdrawn, Assistance Publique - Hôpitaux de Paris | N=110 --> 0 | Recruiting --> Withdrawn

P1, N=34, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Dec 2026 --> Mar 2026

Patient was managed acutely with calcitonin and was started on prednisone and hydroxychloroquine. The co-occurrence of both MEN 2A and sarcoidosis is rare, adding an unexpected layer of complexity to the diagnosis. The rarity of sarcoidosis co-occurring with MEN 2A highlights the importance of considering a broad differential diagnosis, even in patients with known genetic syndromes, to ensure accurate management.

P1, N=62, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

P4, N=300, Active, not recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Active, not recruiting